Organovo (ONVO +2.7%) ended FQ3 with $49.9M in cash/equivalents and restricted cash, down from $53.4M at the end of FQ1. The company reiterates it's on track to release a liver toxicity assay product later in 2014.
FQ3 R&D spend more than doubled Y/Y to $2.36M. SG&A spend rose 12% to $2.4M.
FQ3 results, PR